Cristina Pirlog

TL;DR: In this article , the authors sought to identify the answers to four questions: 1. what type of cancer has more severe hypersensitivity reactions to Nivolumab, 2. what is the time frame for developing these severe reactions to nivolumaab, 3. whether it is best to continue or stop the treatment after a severe hypersensitive reaction to NIVolumaba, and 4. what severe hypersensation reactions are the most frequent reported along Nivilumab treatment.

TL;DR: Bearing in mind all of these risk factors for poor outcomes in cancer patients with solid tumors presenting with Covid-19 can help the treating oncologists make personalized decisions about patient care during the pandemic is helpful.

TL;DR: In this article , the authors established the important idea that resistance to combined therapy (CDK4/6i + ET) can be due to resistance to endocrine therapy, to treatment with CDK 4 and 6 inhibitors, or to both.

TL;DR: NLR proved to be a significant prognostic factor for progression-free survival (PFS) and the combined PD-L1 and NLR prognosticfactor was statistically relevant, while PD- L1 expression was not a valid prognostic factors for progression or death in either univariate or multivariate analysis.

TL;DR: In this article , the authors report a real-world experience of rechallenging with abemaciclib after the prior reaction of grade 4 liver toxicity to ribociclib, with high transaminases values of more than 27 times the upper limit of normal (ULN).